Evaluation of immune responses of stabilised SAT2 antigens of foot-and-mouth disease in cattle

Vaccine

Volumn 35, Issue 40, 2017, Pages 5426-5433

  Scott, Katherine A ^a,b   Rathogwa, N M ^a,b   Capozzo, A V ^c   Maree, Francois F ^a,b  

^a ONDERSTEPOORT VETERINARY INSTITUTE   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA INTA   (Argentina)

Author keywords

Foot and mouth disease virus; SAT2; Thermostable antigen

Indexed keywords

FOOT AND MOUTH DISEASE VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; NEUTRALIZING ANTIBODY; SAT2 ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS RNA; AMINO ACID TRANSPORTER; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFICACY; FOOT AND MOUTH DISEASE; IMMUNE RESPONSE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SANGA CATTLE; SHELF LIFE; THERMOSTABILITY; VIRUS ISOLATION; ANIMAL; BOVINE; FOOT AND MOUTH DISEASE VIRUS; IMMUNOLOGY; PATHOGENICITY; SERODIAGNOSIS;

AMINO ACID TRANSPORT SYSTEM A; ANIMALS; ANTIBODIES, NEUTRALIZING; CATTLE; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; NEUTRALIZATION TESTS; VIRAL VACCINES;

EID: 85017570240     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.02.003     Document Type: Article

References (50)

1. Rweyemamu, M., Roeder, P., MacKay, D., Sumption, K., Brownlie, J., Leforban, Y., Planning for the progressive control of foot-and-mouth disease worldwide. Transbound Emerg Dis 55 (2008), 73–87.
2. Rweyemamu, M., Roeder, P., Mackay, D., Sumption, K., Brownlie, J., Leforban, Y., et al. Epidemiological patterns of foot-and-mouth disease worldwide. Transbound Emerg Dis 55 (2008), 57–72.
3. Ayebazibwe, C., Mwiine, F.N., Tjornehoj, K., Balinda, S.N., Muwanika, V.B., Ademun Okurut, A.R., et al. The role of African buffalos (Syncerus caffer) in the maintenance of foot-and-mouth disease in Uganda. BMC Vet Res, 6, 2010, 54.
4. Bengis, R.G., Kock, R.A., Fischer, J., Infectious animal diseases: the wildlife/livestock interface. Rev Sci Tech 21 (2002), 53–65.
5. Condy, J.B., Hedger, R.S., Hamblin, C., Barnett, I.T., The duration of the foot-and-mouth disease virus carrier state in African buffalo (i) in the individual animal and (ii) in a free-living herd. Comp Immunol Microbiol Infect Dis 8 (1985), 259–265.
6. Hedger, R.S., Condy, J.B., Golding, S.M., Infection of some species of African wild life with foot-and-mouth disease virus. J Comp Pathol 82 (1972), 455–461.
7. Vosloo, W., Bastos, A.D., Kirkbride, E., Esterhuysen, J.J., van Rensburg, D.J., Bengis, R.G., et al. Persistent infection of African buffalo (Syncerus caffer) with SAT-type foot-and-mouth disease viruses: rate of fixation of mutations, antigenic change and interspecies transmission. J Gen Virol 77 (1996), 1457–1467.
8. Bastos, A.D., Anderson, E.C., Bengis, R.G., Keet, D.F., Winterbach, H.K., Thomson, G.R., Molecular epidemiology of SAT3-type foot-and-mouth disease. Virus Genes 27 (2003), 283–290.
9. Bastos, A.D., Haydon, D.T., Sangare, O., Boshoff, C.I., Edrich, J.L., Thomson, G.R., The implications of virus diversity within the SAT 2 serotype for control of foot-and-mouth disease in sub-Saharan Africa. J Gen Virol 84 (2003), 1595–1606.
10. Bastos, A.D., Haydon, D.T., Forsberg, R., Knowles, N.J., Anderson, E.C., Bengis, R.G., et al. Genetic heterogeneity of SAT-1 type foot-and-mouth disease viruses in southern Africa. Arch Virol 146 (2001), 1537–1551.
11. Bastos, A.D., Boshoff, C.I., Keet, D.F., Bengis, R.G., Thomson, G.R., Natural transmission of foot-and-mouth disease virus between African buffalo (Syncerus caffer) and impala (Aepyceros melampus) in the Kruger National Park, South Africa. Epidemiol Infect 124 (2000), 591–598.
12. Dawe, P.S., Flanagan, F.O., Madekurozwa, R.L., Sorensen, K.J., Anderson, E.C., Foggin, C.M., et al. Natural transmission of foot-and-mouth disease virus from African buffalo (Syncerus caffer) to cattle in a wildlife area of Zimbabwe. Vet Rec 134 (1994), 230–232.
13. Thomson, G.R., Vosloo, W., Bastos, A.D., Foot and mouth disease in wildlife. Virus Res 91 (2003), 145–161.
14. Doel, T.R., Baccarini, P.J., Thermal stability of foot-and-mouth disease virus. Arch Virol 70 (1981), 21–32.
15. Doel, T.R., FMD vaccines. Virus Res 91 (2003), 81–99.
16. Hunter, P., Vaccination as a means of control of foot-and-mouth disease in sub-saharan Africa. Vaccine 16 (1998), 261–264.
17. Maree, F.F., Blignaut, B., Esterhuysen, J.J., de Beer, T.A., Theron, J., O'Neill, H.G., et al. Predicting antigenic sites on the foot-and-mouth disease virus capsid of the South African Territories types using virus neutralization data. J Gen Virol 92 (2011), 2297–2309.
18. Piccone, M.E., Diaz-San Segundo, F., Kramer, E., Rodriguez, L.L., de los Santos, T., Introduction of tag epitopes in the inter-AUG region of foot and mouth disease virus: effect on the L protein. Virus Res 155 (2011), 91–97.
19. Rieder, E., Baxt, B., Lubroth, J., Mason, P.W., Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV. J Virol 68 (1994), 7092–7098.
20. Kotecha, A., Seago, J., Scott, K., Burman, A., Loureiro, S., Ren, J., et al. Structure-based energetics of protein interfaces guides foot-and-mouth disease virus vaccine design. Nat Struct Mol Biol 22 (2015), 788–794.
21. Mateo, R., Luna, E., Rincon, V., Mateu, M.G., Engineering viable foot-and-mouth disease viruses with increased thermostability as a step in the development of improved vaccines. J Virol 82 (2008), 12232–12240.
22. Zibert, A., Maass, G., Strebel, K., Falk, M.M., Beck, E., Infectious foot-and-mouth disease virus derived from a cloned full-length cDNA. J Virol 64 (1990), 2467–2473.
23. Maree, F.F., Nsamba, P., Mutowembwa, P., Rotherham, L.S., Esterhuysen, J., Scott, K.A., Intra-serotype SAT2 chimeric foot-and-mouth disease vaccine protects cattle against FMDV challenge. Vaccine 33 (2015), 2909–2916.
24. Fowler, V.L., Paton, D.J., Rieder, E., Barnett, P.V., Chimeric foot-and-mouth disease viruses: evaluation of their efficacy as potential marker vaccines in cattle. Vaccine 26 (2008), 1982–1989.
25. Maree, F.F., Scott, K.A., Opperman, P.A., Chitray, M., Sallu, R., Sinkala, Y., et al. Prospects for the control of foot-and-mouth disease: an African perspective. J Vet Med 5 (2014), 119–138.
26. Maree, F.F., Blignaut, B., de Beer, T.A., Visser, N., Rieder, E.A., Mapping of amino acid residues responsible for adhesion of cell culture-adapted foot-and-mouth disease SAT type viruses. Virus Res 153 (2010), 82–91.
27. Storey, P., Theron, J., Maree, F.F., O'Neill, H.G., A second RGD motif in the 1D capsid protein of a SAT1 type foot-and-mouth disease virus field isolate is not essential for attachment to target cells. Virus Res 124 (2007), 184–192.
28. Mateo, R., Diaz, A., Baranowski, E., Mateu, M.G., Complete alanine scanning of intersubunit interfaces in a foot-and-mouth disease virus capsid reveals critical contributions of many side chains to particle stability and viral function. J Biol Chem 278 (2003), 41019–41027.
29. Filman, D.J., Syed, R., Chow, M., et al. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J 8 (1989), 1567–1579.
30. Airaksinen, A., Roivainen, M., Hovi, T., Coxsackievirus A9 VP1 mutants with enhanced or hindered A particle formation and decreased infectivity. J Virol 75 (2001), 952–960.
31. Mateo, R., Luna, E., Mateu, M.G., Thermostable variants are not generally represented in foot-and-mouth disease virus quasispecies. J Gen Virol 88 (2007), 859–864.
32. Twomey, T., Newman, J., Burrage, T., et al. Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines. Vaccine 13 (1995), 1603–1610.
33. Capozzo, A.V.E., Periolo, O.H., Robiolo, B., Seki, C., La Torre, J.L., Grigera, P.R., Total and isotype humoral responses in cattle vaccinated with foot and mouth disease virus (FMDV) immunogen produced either in bovine tongue tissue or in BHK-21 cell suspension cultures. Vaccine 15 (1997), 624–630.
34. Barnett, P.V., Statham, R.J., Vosloo, W., Haydon, D.T., Foot-and-mouth disease vaccine potency testing: determination and statistical validation of a model using a serological approach. Vaccine 21 (2003), 3240–3248.
35. Opperman, P.A., Maree, F.F., Van Wyngaardt, W., Vosloo, W., Theron, J., Mapping of antigenic determinants on a SAT2 foot-and-mouth disease virus using chicken single-chain antibody fragments. Virus Res 167 (2012), 370–379.
36. Van Rensburg, H.G., Henry, T.M., Mason, P.W., Studies of genetically defined chimeras of a European type A virus and a South African Territories type 2 virus reveal growth determinants for foot-and-mouth disease virus. J Gen Virol 85 (2004), 61–68.
37. Brehm, K.E., Ferris, N.P., Lenk, M., Riebe, R., Haas, B., Highly sensitive fetal goat tongue cell line for detection and isolation of foot-and-mouth disease virus. J Clin Microbiol 47 (2009), 3156–3160.
38. Doel, T.R., Mowat, G.N., An international collaborative study on foot and mouth disease virus assay methods 2 Quantification of 146S particles. J Biol Stand 13 (1985), 335–344.
39. OIE. Manual of diagnostic tests and vaccines for terrestrial animals. Office Paris: International des Epizooties; 2012.
40. Kärber, G., Beitrag zur kollektiven Behandlung pharmakologischer reihenversuche. Path u Pharmakol 162 (1931), 480–483.
41. Sorensen, K.J., Madsen, K.G., Madsen, E.S., Salt, J.S., Nqindi, J., Mackay, D.K.J., Differentiation of infection from vaccination in foot-and-mouth disease by the detection of anti-bodies to the non-structural proteins 3D, 3AB and 3ABC in ELISA using antigens expressed in baculovirus. Arch Virol 143 (1998), 1461–1476.
42. Bucafusco, D., DiGiacomo, S., Pega, J., Schammas, J.M., Cardoso, N., Capozzo, A.V., et al. Foot-and-mouth disease vaccination induces cross-reactive IFN-γ responses in cattle that are dependent on the integrity of the 140S particles. Virology 476 (2015), 11–18.
43. Rieder, E., Bunch, T., Brown, F., Mason, P.W., Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J Virol 67 (1993), 5139–5145.
44. Callahan, J.D., Brown, F., Osorio, F.A., Sur, J.H., Kramer, E., Long, G.W., et al. Use of a portable real-time reverse transcriptase-polymerase chain reaction assay for rapid detection of foot-and-mouth disease virus. J Am Vet Med Assoc 220 (2002), 1636–1642.
45. Schiller, I., Waters, W.R., Vordermeier, H.M., Nonnecke, B., Welsh, M., Keck, N., et al. Optimization of a whole-blood gamma interferon assay for detection of Mycobacterium bovis-infected cattle. Clin Vacc Immun 16 (2009), 1196–1202.
46. Lazarus DD, Burroughs R, van Schalkwyk L, Maree FF, Thomson GR, Fosgate GT. Vaccination and control of FMD in cattle at livestock-wildlife interface areas of the Kruger National Park South Africa. In: Conf proceedings. GFRA conference, Tanzania; 2013. p. 4.
47. Scott, K., Kotecha, A., Fry, E.E., Stuart, D.I., Charleston, B., Maree, F.F., Engineering structurally modified SAT2 viruses for increased thermostability. Vaccine, 2017 in press.
48. Brehm, K.E., Kumar, N., Thulke, H.H., Haas, B., High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus. Vaccine 26 (2008), 1681–1687.
49. Cox, S.J., Aggarwal, N., Statham, R.J., Barnett, P.V., Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines. Vaccine 21 (2003), 1336–1347.
50. Barnett, P.V., Samuel, A.R., Pullen, L., Ansell, D., Butcher, R.N., Parkhouse, R.M.E., Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse. J Gen Virol 79 (1998), 1687–1697.